Ask AI
ProCE Banner Activity

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Podcast Episodes

Listen to expert perspectives on selecting optimal therapy for patients with CLL, with a focus on how BTK inhibitor resistance mutations are assessed and how they affect therapy choice. 

Released: October 01, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca

Disclosure

Primary Author

Matthew S Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc: consultant/advisor/speaker: AbbVie, Ascentage, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Eli Lilly, Genmab, Janssen, Merck, Nuvalent, Schroedinger.

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Lindsey Roeker, MD: consultant/advisor/speaker: AbbVie, Ascentage, AstraZeneca, BeiGene, Curio, DAVA, Janssen, Loxo Oncology, Pharmacyclics, Pfizer; data and safety monitoring committee: Ascentage; owner (minority ownership interest): Abbott; researcher (paid to institution): AbbVie, Adaptive Biotechnologies, Aptose Biosciences, AstraZeneca, Dren Bio, Genentech, Loxo Oncology, Pfizer, Qilu Puget Sound Biotherapeutics.